Project Grant R01AI192048
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$1.4M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $793,247 to the University of North Carolina at Chapel Hill to conduct research aimed at improving the health of people living with HIV across the lifespan. The key products and services to be delivered include: Developing and implementing a data-driven algorithm to assign validated causes for hospitalizations among people with HIV, and using...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,788 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Quantifying Genomic and Pharmacometabolomic Differences in Antiretroviral Exposure in MACS/WIHS Combined Cohort Study", aims to identify genetic and metabolic factors that influence the plasma concentrations and associated...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,314,701.00 to support research focused on optimizing dolutegravir-based antiretroviral therapy (ART) in children and adolescents. The primary award recipient is the University of Florida, which will oversee the overall research project. The project includes sub-awards to Kwame Nkrumah University of Science...
This federal Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $884,322 to support research into the mechanisms that create and sustain the HIV reservoir - a population of latently infected cells that persists during suppressive antiretroviral therapy and prevents a cure for HIV. The research team, led by Dr. Reeves and collaborators at the Fred Hutchinson Cancer...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...
This $775,391 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to investigate the role of the human protein galectin-9 in HIV persistence and the establishment of the long-term viral reservoir. The primary awardee, Vitalant Research Institute, will conduct in vitro studies to elucidate the molecular and immunological mechanisms underlying galectin-9's impact on the HIV reservoir. Additionally,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,224 to the University of Chicago to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to gain a deeper mechanistic understanding of HIV assembly, maturation, and uncoating processes, with a focus on the roles of viral RNA, host cell factors, and...
This federal Project Grant award of $169,811, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research conducted by the University of North Carolina at Chapel Hill (UNC-CH) to develop and apply innovative statistical methods for estimating the overall and spillover effects of infectious disease prevention interventions. The primary goal is to acquire training in infectious disease...
This $394,723 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research by Texas Tech University Health Sciences Center (TTUHSC) to investigate the role of pulmonary arterial smooth muscle cells (PVSMC) as potential HIV reservoirs. The key objectives are to determine PVSMC's ability to support chronic HIV infection, spread the virus to immune cells during antiretroviral...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $208,575 to develop an ionic liquid-based nanoemulsion containing a combination of antiretroviral drugs for the oral and transdermal treatment of HIV infection. The goal is to improve the oral bioavailability and skin permeability of the integrase inhibitor dolutegravir and the non-nucleoside reverse...